Live
- BJP MP candidate Bharat Prasad visited the student who tried to commit suicide
- PM’s popularity in the fast lane: Autos with 'Har Dil Mein Modi' slogan spotted across Delhi
- Delhi-based political parties are like East India Company: Sukhbir Badal
- Golf: Diksha moves into Top-20 at South African Women’s Open
- KCR lashes out against BJP and Congress for destroying Telangana
- Dairy Science students visited the Milk cooling plant
- Moody feels Pant ahead in keepers’ race for T20 WC squad; Srikkanth picks Rahul over Samson as reserve keeper
- Thanking voters for extending 'unparalleled support' to NDA, PM Modi says second phase 'too good'
- Natural Relief for Menstrual Cramps: Beetroot Juice Recipe
- Asha Worker died in a road accident
Cipla inks pact with US co for Ropivacaine infusion system
Drug major Cipla has inked a pact with US-based BioQ Pharma for registration and commercialisation of latter\'s Ropivacaine infusion system, used in treating post-operative pain, in India.
New Delhi : Drug major Cipla has inked a pact with US-based BioQ Pharma for registration and commercialisation of latter's Ropivacaine infusion system, used in treating post-operative pain, in India. BioQ Pharma and Cipla have inked a strategic distribution, supply and development agreement for the registration and commercialisation of BioQ Pharma's Ropivacaine infusion pharmaceutical in India, the companies said in a joint statement.
"We believe this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain," Cipla's India Business Head, Nikhil Chopra said. BioQ Pharma's unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.
In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQ Pharma, President and CEO, Josh Kriesel said the company is excited to collaborate with Cipla and expand its worldwide commercial footprint into India.
"We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals," he added. Cipla's proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to India's healthcare market, Kriesel said.
